Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie Dreyer

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
The Oncologist|May 8, 2026
In ReplyMarie Dreyer, Al B Benson Iii
British Journal of Haematology|May 25, 2023
A safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpuraOluwatobi Odetola, Karlyn A Martin, Marie Dreyer, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|February 23, 2026
Survivorship Navigator: Personalized Survivorship Care Plan Generation using Large Language ModelsJathurshan Pradeepkumar, Shivam Pankaj Kumar, Courtney Bryce Reamer, et al.
NPJ Breast Cancer|March 15, 2022
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savingsPo-Hung Hsieh, Alec J Kacew, Marie Dreyer, et al.
Breast Cancer Research and Treatment|November 23, 2024
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltrationMargarite D Matossian, Christine Shiang, Deniz Nesli Dolcen, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
The Oncologist|May 8, 2026
In ReplyMarie Dreyer, Al B Benson Iii
British Journal of Haematology|May 25, 2023
A safe and effective use of caplacizumab in pregnancy-related acquired thrombotic thrombocytopenic purpuraOluwatobi Odetola, Karlyn A Martin, Marie Dreyer, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|February 23, 2026
Survivorship Navigator: Personalized Survivorship Care Plan Generation using Large Language ModelsJathurshan Pradeepkumar, Shivam Pankaj Kumar, Courtney Bryce Reamer, et al.
NPJ Breast Cancer|March 15, 2022
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savingsPo-Hung Hsieh, Alec J Kacew, Marie Dreyer, et al.
Breast Cancer Research and Treatment|November 23, 2024
High tumor glucocorticoid receptor expression in early-stage, triple-negative breast cancer is associated with increased T-regulatory cell infiltrationMargarite D Matossian, Christine Shiang, Deniz Nesli Dolcen, et al.
Pageof 1